News for Agent

Daily business news: funding, M&A, launches

Leadership

Swiss Biotech Association Picks Abionic Founder Nicolas Durand as Next CEO

By ·

Key takeaways

  • Nicolas Durand will become CEO of the Swiss Biotech Association on January 1, 2027.
  • Durand founded Abionic in 2010, led it until 2024 and raised approximately CHF 120 million.
  • Odile Rundquist joins the association in December as Chief Strategy & Growth Officer.
  • Matthias Peterhans takes over CSEM from Jens Krauss, and Michael Sauter returns to Empa.

Nicolas Durand will become CEO of the Swiss Biotech Association on January 1, 2027, the association said, succeeding Michael Altorfer, who is stepping down after 10 years. Durand founded Abionic in 2010, led it until 2024 and raised approximately CHF 120 million. startupticker.ch reported the appointment alongside two other leadership changes in Swiss research institutions.

Durand's Mandate at the Swiss Biotech Association

Durand is CEO of Fondation Campus Biotech Geneva and Vice President of economiesuisse. In the new role he will oversee the association's operations, finances and external representation, and implement the strategy approved by the board. The association negotiates framework conditions for the Swiss biotech industry and works on access to talent, novel technologies and financial resources.

Odile Rundquist will join the association in December as Chief Strategy & Growth Officer, working alongside the CEO on strategic growth initiatives, investor and pharmaceutical partner engagement, and international positioning. She brings more than 20 years of experience in life sciences, investment and corporate governance, and is a partner at Bioqube Ventures, with a background in pharmaceutical equity research, family office advisory and venture capital.

Peterhans Takes Over CSEM From Krauss

Matthias Peterhans, a medtech entrepreneur, has taken over the leadership of CSEM from Jens Krauss after three decades of work in digital health. Under Krauss, CSEM advanced optical health-monitoring technologies that now appear in products from Tissot and Festina, and Signant Health (formerly ActiGraph) uses CSEM technology in clinical studies. Peterhans co-founded and led CAScination AG, taking surgical navigation technologies through clinical validation, CE marking, FDA clearance and commercialization, and later co-founded ender diagnostics AG, where he helped scale a diagnostic product and service provider from five to more than 200 employees. He is currently COO of Xovis AG.

Michael Sauter Returns to Empa

Michael Sauter is back at EMPA to strengthen the glatec business incubator and the Empa entrepreneurship team. A former Empa scientist, spin-off founder and startup coach, he will help develop and implement a strategic plan for entrepreneurship and spin-off support at Empa, and coach startups and organize seminars and workshops. Sauter began his career at Empa as a project manager before co-founding the Empa spin-off compliant concept in 2010, and later led innovation centers including ZID Bernpark AG and be-advanced.

Earlier Moves in the Association's Leadership

In July 2026, BioAlps reported that Altorfer, CEO of the Swiss Biotech Association, was stepping down after 10 years and would remain until a successor was appointed, supporting the transition through key 2027 milestones. In June 2026, startupticker.ch reported that the BIO International Convention 2026 would take place from June 22 to 25 in San Diego, California, with a Swiss pavilion featuring 21 startups and established companies.

Companies in this story

Sources

Machine-readable: Markdown · JSON